AR078115A1 - Compuestos eteres aralquil bencilicos, proceso de preparacion de los mis-mos, compuestos intermediarios, uso de dichos compuestos, composicion farmaceutica y medicamento que contiene dichos compuestos - Google Patents

Compuestos eteres aralquil bencilicos, proceso de preparacion de los mis-mos, compuestos intermediarios, uso de dichos compuestos, composicion farmaceutica y medicamento que contiene dichos compuestos

Info

Publication number
AR078115A1
AR078115A1 ARP100103171A ARP100103171A AR078115A1 AR 078115 A1 AR078115 A1 AR 078115A1 AR P100103171 A ARP100103171 A AR P100103171A AR P100103171 A ARP100103171 A AR P100103171A AR 078115 A1 AR078115 A1 AR 078115A1
Authority
AR
Argentina
Prior art keywords
compounds
microorganisms
derivatives
aryl
halogen
Prior art date
Application number
ARP100103171A
Other languages
English (en)
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43627099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078115(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of AR078115A1 publication Critical patent/AR078115A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente describe nuevos compuestos antifungicos que son éteres aralquil bencílicos, de la formula (1) donde: Ar representa arilo, imidazolilo, 1,2,4-triazolilo o bencimidazolilo; R1, R2, R4 y R5 representan, en forma independiente, hidrogeno, halogeno, alquilo C1-6; R3 representa halogeno, alquilo C1-6 u O-R', donde R' representa hidrogeno o alquilos inferiores; R6 representa arilo, arilo sustituido, trifluorometilo, triclorometilo u O-R', donde R' representa hidrogeno o alquilos inferiores, siendo los sustituyentes del arilo un halogeno o un radical tetrazolilo; n y m representan, en forma independiente, un numero entero comprendido entre 0 y 5; con la condicion de que, cuando Ar fuera imidazolilo, R3 fuera cloro, R6 fuera p-fenilo y R1, R2, R4 y R5 fueran hidrogenos, n deba ser diferente de 2, y cuando n y m fuera diferente de 0 y 1, R3 o R6 puedan ser representados por sustituyentes no necesariamente iguales. La presente también se refiere a las sales, solvatos, prodrogas, ésteres, enantiomeros y/o diastereoisomeros farmacéuticamente aceptables, o mezclas de dichos compuestos, a los procesos para la preparacion de dichos compuestos, a los compuestos intermediarios, a las composiciones farmacéuticas que comprenden dichos compuestos y/o derivados, a los medicamentos que comprenden dichos compuestos y/o derivados, como así también a los usos y métodos de dichos compuestos y/o derivados para el tratamiento y/o la prevencion de condiciones y/o enfermedades causadas por microorganismos tales como hongos, bacterias y/o protozoarios, para la inhibicion de la proliferacion y/o supervivencia de dichos microorganismos, para el tratamiento y/o la prevencion de la colonizacion de microorganismos en un individuo, y para la fabricacion de un medicamento.
ARP100103171A 2009-08-28 2010-08-30 Compuestos eteres aralquil bencilicos, proceso de preparacion de los mis-mos, compuestos intermediarios, uso de dichos compuestos, composicion farmaceutica y medicamento que contiene dichos compuestos AR078115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0904249-0A BRPI0904249B1 (pt) 2009-08-28 2009-08-28 Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica

Publications (1)

Publication Number Publication Date
AR078115A1 true AR078115A1 (es) 2011-10-12

Family

ID=43627099

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103171A AR078115A1 (es) 2009-08-28 2010-08-30 Compuestos eteres aralquil bencilicos, proceso de preparacion de los mis-mos, compuestos intermediarios, uso de dichos compuestos, composicion farmaceutica y medicamento que contiene dichos compuestos

Country Status (24)

Country Link
US (1) US8975289B2 (es)
EP (1) EP2471781B1 (es)
JP (1) JP5718334B2 (es)
KR (1) KR101765752B1 (es)
CN (1) CN102625800A (es)
AR (1) AR078115A1 (es)
AU (1) AU2010286266B2 (es)
BR (1) BRPI0904249B1 (es)
CA (1) CA2771044C (es)
CL (1) CL2012000463A1 (es)
DK (1) DK2471781T3 (es)
ES (1) ES2606168T3 (es)
HU (1) HUE032199T2 (es)
IL (1) IL218044A (es)
IN (1) IN2012DN00611A (es)
MX (1) MX2012002276A (es)
PE (1) PE20120921A1 (es)
PL (1) PL2471781T3 (es)
PT (1) PT2471781T (es)
RU (1) RU2548009C2 (es)
SG (1) SG178298A1 (es)
UA (1) UA108479C2 (es)
WO (1) WO2011022798A1 (es)
ZA (1) ZA201201442B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579829B (zh) * 2012-03-06 2013-09-18 康莉 一种治疗牛放线菌病的中药组合物及其制备方法
CN104016837B (zh) * 2014-05-26 2016-08-24 武汉有机实业有限公司 4,4’-二甲基二苄基醚的制备方法
RU2603622C1 (ru) * 2015-06-25 2016-11-27 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Комплексный метод лечения тейлериоза мелкого рогатого скота
CN108047147A (zh) * 2017-12-08 2018-05-18 长江大学 一类三唑类化合物以及作为杀菌剂的用途
KR101983575B1 (ko) * 2017-12-21 2019-06-03 대한민국 신균주 세라토바시디움 속 js1289 및 이의 용도
US20220267280A1 (en) * 2019-08-16 2022-08-25 Purdue Research Foundation Small molecule stimulators of the core particle of the proteasome

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SU557755A3 (ru) 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
DE2333354C2 (de) * 1973-06-30 1983-12-15 Bayer Ag, 5090 Leverkusen 2-Aryloxy-2-(imidazol-1-yl)-äthanole sowie deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide
GB1475271A (en) 1975-04-30 1977-06-01 Pfizer Ltd 1-aryl-2-1-imidazolyl-alkyl ethers and thioethers and their use as antifungal agents
DE2556319A1 (de) * 1975-12-13 1977-06-23 Basf Ag Substituierte triazol-aether
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4277475A (en) * 1979-01-11 1981-07-07 Syntex (U.S.A.) Inc. Contraceptive methods employing 1-substituted imidazole derivatives
BE885957A (nl) 1980-10-31 1981-04-30 Amylum Graanderivaten Raff Inrichting voor de continue bereiding van zetmeellijm
US4368186A (en) 1981-05-07 1983-01-11 Syntex (U.S.A.) Inc. Methods and compositions for intravaginal contraception
DE3314738A1 (de) * 1983-04-23 1984-10-25 Bayer Ag, 5090 Leverkusen Azolylethyl-benzyl-ether-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
JP2875140B2 (ja) * 1993-08-16 1999-03-24 明治製菓株式会社 抗ｍｒｓａ組成物
US5461068A (en) 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
WO2006081327A2 (en) * 2005-01-25 2006-08-03 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
GB0714226D0 (en) * 2007-07-20 2007-08-29 Therapeutics Ltd E anti-bacterial combination therapy
GB0724996D0 (en) * 2007-12-21 2008-01-30 Therapeutics Ltd E Antibacterial combination therapy for the treatment of gram positive bacterial infections
GB0813211D0 (en) * 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
EP2331094A4 (en) * 2008-08-29 2011-10-26 Uab Research Foundation NOVEL AGENT AGAINST ARTHHYTHMIA

Also Published As

Publication number Publication date
MX2012002276A (es) 2012-04-19
EP2471781A4 (en) 2013-01-23
PE20120921A1 (es) 2012-08-01
US8975289B2 (en) 2015-03-10
US20120196908A1 (en) 2012-08-02
IL218044A0 (en) 2012-04-30
AU2010286266A1 (en) 2012-04-05
HUE032199T2 (en) 2017-08-28
EP2471781B1 (en) 2016-09-07
CL2012000463A1 (es) 2012-09-21
AU2010286266B2 (en) 2015-02-12
WO2011022798A1 (pt) 2011-03-03
UA108479C2 (en) 2015-05-12
KR20120050490A (ko) 2012-05-18
ZA201201442B (en) 2012-10-31
DK2471781T3 (da) 2017-01-02
RU2548009C2 (ru) 2015-04-10
KR101765752B1 (ko) 2017-08-07
ES2606168T3 (es) 2017-03-23
PL2471781T3 (pl) 2017-08-31
SG178298A1 (en) 2012-03-29
RU2012110925A (ru) 2013-10-10
JP2013503111A (ja) 2013-01-31
JP5718334B2 (ja) 2015-05-13
PT2471781T (pt) 2016-12-15
IL218044A (en) 2017-02-28
IN2012DN00611A (es) 2015-06-12
BRPI0904249B1 (pt) 2018-03-06
BRPI0904249A2 (pt) 2011-05-17
CA2771044A1 (en) 2011-03-03
CN102625800A (zh) 2012-08-01
EP2471781A1 (en) 2012-07-04
CA2771044C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
AR078115A1 (es) Compuestos eteres aralquil bencilicos, proceso de preparacion de los mis-mos, compuestos intermediarios, uso de dichos compuestos, composicion farmaceutica y medicamento que contiene dichos compuestos
ECSP16062174A (es) Análogos de cortistatina y síntesis y usos de los mismos
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
ECSP055633A (es) Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos
DOP2012000225A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
MX2009013935A (es) Compuestos quimicos.
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY32025A (es) Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones.
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
PE20150706A1 (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
MX2017009824A (es) Triazoles sustituidos y metodos relacionados a estos.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
DOP2023000281A (es) Inhibidores de mutación de her2
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2023001576A (es) Síntesis de nuevos derivados de imipridona y su evaluación de su actividad anticáncerigena.
JOP20200089A1 (ar) مشتقات جديدة ضخمة الحلقات وعملية لتحضيرها والتركيبات الصيدلية التى تحتوي عليها
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.
WO2020006031A8 (en) Ask1 inhibiting agents
MX2020014327A (es) Nuevos derivados de amino-pirimidonilo un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CR20120131A (es) Uso de derivados del indol como activadores de nurr-1, para su aplicación como medicamento en el tratamiento de la enfermedad de parkinson

Legal Events

Date Code Title Description
FG Grant, registration